Literature DB >> 24823400

Methicillin-resistant Staphylococcus aureus colonization and disease severity in atopic dermatitis: a cross-sectional study from South India.

Soumya Jagadeesan, George Kurien1, Manjula Velikkakathu Divakaran, Sadeep Melethil Sadanandan, K Sobhanakumari, A Sarin.   

Abstract

BACKGROUND: Colonization by methicillin-resistant Staphylococcus aureus (MRSA) in atopic dermatitis is little studied but has therapeutic implications. It may have a role in disease severity given the additional virulence factors associated. AIMS: Our aims were to record the proportion of patients with MRSA colonization in atopic dermatitis and to ascertain if any association exists between MRSA colonization and disease severity.
METHODS: An observational cross-sectional study involving children aged≤12 years with atopic dermatitis attending the outpatient department of Government Medical College, Kottayam was conducted. Socio-demographic data, exacerbating factors and risk factors for hospital care-associated MRSA were documented. Extent of atopic dermatitis was recorded using a standardized scale (Eczema Area Severity Index, EASI). Skin swabs were taken from anterior nares and the worst affected atopic dermatitis sites for culture and sensitivity.
RESULTS: Of the 119 subjects recruited during the study period (November 2009-April 2011), Staphylococcus aureus was isolated from 110 (92.4%) patients and MRSA from 30 (25.21%) patients. A total of 18 patients with MRSA had risk factors for healthcare associated-MRSA. The patients whose cultures grew MRSA were found to have significantly higher EASI score when compared to those patients colonized with methicillin sensitive Staphylococcus aureus (P < 0.01). Presence of Staphylococcus aureus, early age of onset, presence of food allergies, seasonal exacerbation and inadequate breastfeeding did not seem to influence disease severity.
CONCLUSIONS: There is a high degree of prevalence of MRSA (25.2%) in atopic dermatitis and presence of MRSA is associated with increased disease severity. Further studies are needed to validate these findings.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24823400     DOI: 10.4103/0378-6323.132250

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN: 0378-6323            Impact factor:   2.545


  6 in total

1.  Interventions to reduce Staphylococcus aureus in the management of eczema.

Authors:  Susannah Mc George; Sanja Karanovic; David A Harrison; Anjna Rani; Andrew J Birnie; Fiona J Bath-Hextall; Jane C Ravenscroft; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-10-29

2.  Relationship Between the Presence of Eczema Herpeticum and the Significance of Clinical and Laboratory Tests in Korean Children With Atopic Dermatitis.

Authors:  Kohwoon Kim; Junseok Kang; Sung Won Kim; Myongsoon Sung
Journal:  Iran J Pediatr       Date:  2016-06-18       Impact factor: 0.364

3.  Clinicoepidemiologic Profile and the Cutaneous and Nasal Colonization with Methicillin-Resistant Staphylococcus aureus in Children with Atopic Dermatitis from North India.

Authors:  Vanya Narayan; Rashmi Sarkar; Krishna Deb Barman; S Krishna Prakash
Journal:  Indian Dermatol Online J       Date:  2019 Jul-Aug

4.  Burden of Disease, Unmet Needs in the Diagnosis and Management of Atopic Dermatitis: An Indian Expert Consensus.

Authors:  Murlidhar Rajagopalan; Amar Jeet Chitkara; Samir Dalwai; Abhishek De; Ram Gulati; Samipa Mukherjee; Sharad Mutalik; Nidhi Sharma; Shrutakirthi Shenoi; Prakash Vaidya; Amod Tilak; Charles Adhav
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-11-22

Review 5.  Bacterial and Viral Infections in Atopic Dermatitis: a Comprehensive Review.

Authors:  Peck Y Ong; Donald Y M Leung
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 10.817

Review 6.  Interactions Between Atopic Dermatitis and Staphylococcus aureus Infection: Clinical Implications.

Authors:  Jihyun Kim; Byung Eui Kim; Kangmo Ahn; Donald Y M Leung
Journal:  Allergy Asthma Immunol Res       Date:  2019-09       Impact factor: 5.764

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.